TrumpRx is not a price-control regime — it’s a discount portal for commonly used drugs, affecting only out-of-pocket buyers.

By leaving insurance-negotiated prices and supply contracts untouched, the program avoids threatening core pharma profits. Investors see it as a narrow, voluntary policy, which helped drive a rally in pharmaceutical stocks.

The wider takeaway: contained policy moves like TrumpRx reduce uncertainty, keeping financial conditions stable and easing pressure on risk assets such as Bitcoin and Ethereum.